According to the latest market research study by Technavio, the global genomics biomarkers market is expected to grow at a CAGR of close to 18% during the forecast period 2017 to 2021.
This report by Technavio provides an in-depth analysis of the global genomics biomarkers market in terms of revenue and emerging market trends. The report also includes an up-to-date vendor analysis and forecasts for various market segments and all geographical regions.
Technavio research analysts categorize the market based on the indication
Source: Technavio
Click here to request a free sample of this report
The top three revenue contributing segments are discussed below
Oncology: Genetic biomarkers are extensively adopted in oncology screening/diagnostic and prognostic tests. For instance, Illumina’s Cancer Discovery Initiative is aimed at identifying genomic and transcriptomics biomarkers for gastric, ovarian, and colorectal cancers.
“Developing multiple-gene biomarker tests for cancers are expected to have a higher predictive value during the forecast period. The multiple cancer biomarkers can be detected using Alderon’s eSystem. Alderon’s eSystem accurately measures cancer biomarkers at a low cost and can also be used for the detection of DNA/RNA of cells,” says Barath Palada, a lead analyst at Technavio for research on in-vitro diagnostics.
Cardiovascular diseases: Genome-wide association studies and linkage analysis have led to the discovery of several gene biomarkers that can be used for improved risk-assessment for cardiovascular disease development. The cardiovascular disease testing using genomic biomarkers indication has been in use for two years. Quest Diagnostics, Ambry Genetics, 23andMe, GeneLogic, Gknowmix, and deCODE Genetics are some of the key participants working in this area.
Exciting read: Better Drug Discovery and Delivery through Genomics
Neurological diseases: Several genomic and transcriptome biomarkers have been discovered for PD, and AD, but the translation of the number of biomarkers discovered to those moving to the clinic is probably the least for this segment. Gene biomarkers are primarily used for risk assessment for nervous system diseases and have limited use for prognosis and drug development.
Ask an analyst to know more about this report
The top vendors operating in the global genomics biomarkers market are:
- Roche Diagnostics
- Myriad Genetics
- QIAGEN
- Thermo Fisher Scientific
- Bio-Rad Laboratories
The other prominent vendors in the market include 23andMe, Aepodia, Almac, AROS Applied Biotechnology, DNAVision, Epigenomics, Epistem, Eurofins Scientific, Foundation Medicine, Genomic Health, Liquid Genomics, New England Biolabs, OriGene, and US Biomarkers.
A more detailed analysis is available in the Technavio report titled, ‘Global Genomics Biomarkers Market 2017-2021’. Technavio also customizes reports by other regions and specific segments upon request.
Other related reports
- Global Immunodiagnostics Market 2017-2021
- Global Neurological Biomarkers Market 2016-2020
- Global Deep Brain Stimulation Market 2016-2020
To read more press releases – click here
For any assistance or query, please contact our media team at:
media@technavio.com
US: +1 630 333 9501
UK: +44 208 123 1770
https://www.technavio.com/
